Mycobacterium tuberculosis, Microbiology, Tuberculosis, Biochemistry and Immunology are his primary areas of study. His Mycobacterium tuberculosis research is multidisciplinary, incorporating perspectives in Immunity, Bacteria, Gene, Virulence and Drug resistance. His research in Microbiology intersects with topics in In vitro, Mycobacterium, Bacilli, Mutant and Isoniazid.
The various areas that Clifton E. Barry examines in his Tuberculosis study include Surgery, Intensive care medicine and Virology. His Biochemistry research is multidisciplinary, incorporating elements of SQ109 and Mycolic acid. His Immunology study combines topics from a wide range of disciplines, such as Global health, Public health, Latent tuberculosis and Disease.
His main research concerns Mycobacterium tuberculosis, Tuberculosis, Microbiology, Biochemistry and Drug resistance. His Mycobacterium tuberculosis study also includes
His Microbiology research includes themes of Mycobacterium, Bacteria and Virulence. His research in Biochemistry focuses on subjects like Mycolic acid, which are connected to Cell wall. His Drug resistance research includes elements of Rifampicin and Pharmacology.
His scientific interests lie mostly in Mycobacterium tuberculosis, Tuberculosis, Biochemistry, Immunology and Microbiology. The concepts of his Mycobacterium tuberculosis study are interwoven with issues in In vitro, Structure–activity relationship, Biosynthesis, Granuloma and Drug discovery. Clifton E. Barry combines subjects such as Disease, Drug resistance and Intensive care medicine with his study of Tuberculosis.
As a part of the same scientific family, Clifton E. Barry mostly works in the field of Biochemistry, focusing on In vivo and, on occasion, Glycosylation, Congenital myasthenic syndrome and Nucleoside. Downregulation and upregulation and T-cell receptor is closely connected to Cell in his research, which is encompassed under the umbrella topic of Immunology. His work on Pathogen as part of general Microbiology research is frequently linked to Aerosol sampling, thereby connecting diverse disciplines of science.
Clifton E. Barry mainly investigates Mycobacterium tuberculosis, Tuberculosis, Immunology, Drug resistance and Microbiology. His Mycobacterium tuberculosis study integrates concerns from other disciplines, such as Inflammation, Biochemistry, Molecular biology, Sputum and Isoniazid. He has included themes like Molecular diagnostics and Virology in his Isoniazid study.
His Tuberculosis research integrates issues from Subclinical infection, Disease and Intensive care medicine. His study looks at the intersection of Drug resistance and topics like Pyrazinamide with Drug tolerance, Potency, Bacilli and Ex vivo. His studies deal with areas such as Oxidase test, Cytochrome, Cytochrome c and Cytochrome c oxidase as well as Microbiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
S. T. Cole;R. Brosch;J. Parkhill;T. Garnier.
Nature (1998)
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Clifton E. Barry;Helena I. Boshoff;Véronique Dartois;Thomas Dick.
Nature Reviews Microbiology (2009)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
C. Kendall Stover;Paul Warrener;Donald R. VanDevanter;David R. Sherman.
Nature (2000)
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response
Michael B. Reed;Pilar Domenech;Claudia Manca;Hua Su.
Nature (2004)
Mycolic acids: structure, biosynthesis and physiological functions.
Clifton E Barry;Richard E Lee;Khisimusi Mdluli;Andrea E Sampson.
Progress in Lipid Research (1998)
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action.
Helena I.M. Boshoff;Timothy G. Myers;Brent R. Copp;Michael R. McNeil.
Journal of Biological Chemistry (2004)
Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β
Claudia Manca;Liana Tsenova;Amy Bergtold;Sherry Freeman.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Treatment of Tuberculosis.
C. Robert Horsburgh;Clifton E. Barry;Christoph Lange.
The New England Journal of Medicine (2015)
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Ramandeep Singh;Ujjini Manjunatha;Ujjini Manjunatha;Helena I. M. Boshoff;Young Hwan Ha.
Science (2008)
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
Katrin D. Mayer-Barber;Bruno B. Andrade;Sandra D. Oland;Eduardo P. Amaral;Eduardo P. Amaral.
Nature (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
Yonsei University
Rutgers, The State University of New Jersey
The Francis Crick Institute
Stellenbosch University
University of Pittsburgh
Bill & Melinda Gates Foundation
Imperial College London
Cornell University
Cornell University
Warsaw University of Technology
Central Queensland University
Chalmers University of Technology
University of California, Davis
Iowa State University
University of Perpignan
Spanish National Research Council
King Abdullah University of Science and Technology
RWTH Aachen University
University of Zurich
Kyoto University
University of Colorado Anschutz Medical Campus
Chinese Academy of Sciences
Fudan University
German Cancer Research Center
Columbia University